VYBRIQUE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYBRIQUE (VYBRIQUE).
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion and lowering blood glucose. Also improves glycemic control and reduces cardiovascular risk in patients with type 2 diabetes.
| Metabolism | Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor CYP-mediated metabolism (CYP3A4). |
| Excretion | Primarily hepatic metabolism with <5% renal excretion of unchanged drug. Biliary/fecal elimination accounts for ~60-70% as metabolites. |
| Half-life | Terminal elimination half-life is 1.0-1.5 hours, consistent with frequent dosing requirement. |
| Protein binding | 94-96% bound to serum proteins, primarily albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd approximately 0.3 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Oral bioavailability is ~70% due to first-pass hepatic metabolism. |
| Onset of Action | Intravenous: within 5 minutes; oral: 30-60 minutes. |
| Duration of Action | Duration of action is 2-4 hours, necessitating multiple daily doses for sustained effect. |
25 mg orally once daily, titrated to 50 mg once daily after 2 weeks, then to 75 mg once daily as tolerated by ECG monitoring.
| Dosage form | FILM |
| Renal impairment | eGFR 15-29 mL/min/1.73m2: 25 mg once daily; eGFR <15 mL/min or on dialysis: not recommended. |
| Liver impairment | Child-Pugh class B: no dose adjustment required; Child-Pugh class C: not studied, contraindicated. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor for QT prolongation due to age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VYBRIQUE (VYBRIQUE).
| Breastfeeding | It is unknown if VYBRIQUE is excreted in human milk. No data on M/P ratio. Due to potential for adverse reactions in breastfed infants, patients should discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | VYBRIQUE (trofinetide) is not expected to increase the risk of major birth defects based on limited human data. In animal studies, no adverse developmental effects were observed at exposures up to 5 times the maximum recommended human dose. However, data are insufficient to rule out risks. Use during pregnancy only if clearly needed. |
■ FDA Black Box Warning
WARNING: RISK OF KETOACIDOSIS IN PATIENTS WITH TYPE 1 DIABETES AND OTHER PATIENTS WITH KETOACIDOSIS PREDISPOSITION. Vybriq should not be used in patients with type 1 diabetes mellitus. Ketoacidosis, including life-threatening cases, has been reported in patients with type 2 diabetes mellitus taking SGLT2 inhibitors. Patients with signs and symptoms of ketoacidosis should be assessed for ketoacidosis regardless of blood glucose levels.
| Serious Effects |
["History of serious hypersensitivity reaction to Vybriq","Severe renal impairment (eGFR <30 mL/min/1.73 m2) or end-stage renal disease","Patients on dialysis"]
| Precautions | ["Ketoacidosis","Volume depletion","Urosepsis and pyelonephritis","Lower limb amputation","Hypoglycemia with concurrent insulin or sulfonylurea use","Genital mycotic infections","Increased LDL-C","Acute kidney injury"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal adverse reactions including gastrointestinal effects (nausea, vomiting, diarrhea) and potential weight loss. Fetal monitoring per standard prenatal care; no specific fetal monitoring required due to drug. |
| Fertility Effects | In animal studies, no adverse effects on fertility were observed. Human data are not available. VYBRIQUE is not expected to impair fertility in females or males. |